GLAXO SMITHKLINE Good PHARMA Stock To Invest

Why GLAXO SMITHKLINE Good PHARMA Stock To Invest?

1. The Indian subsidiary of the world’s second largest drug maker GlaxoSmithKline Plc., Glaxo SmithKline.
2. GLAXO SMITHKLINE or GSK Ltd has posted a flat set of results 5.28% growth in net sales at Rs1,660.41 crore for the full year.
3. GSK Ltd launched patented cancer drug Tykerb and cardiac drug Olmesarten through a licensing deal with Japan’s Daiichi Sankyo Co. Ltd, and anti-fungal drug Micafungin.
4. The company also plans to launch at least four new products in the coming months, which will also include Cervarix, the company’s much touted cervical cancer vaccine. By 2010, it also plans to launch Streptococcus pneumonia vaccine.
5. The company is now scouting for acquisitions in the domestic market to consolidate its Indian business. It has a cash balance of Rs.1500 crore which it plans to utilize for this acquisition.
6. Conclusion

GSK Ltd is the largest multinational drug player operating in the Indian market and best to stay invested with this stock for the long run. Thanks